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Abstract
The study uses Fourier Transform Infrared (FTIR) spectroscopy to identify five Nevirapine (NV) co-crystals,
determines the dissolution profile of the co-crystals and the antiviral activity comparative to pure NV.
Hot stage microscopy measured the purity and integrity of each co-crystal. FTIR analysis was used to identify the
co-crystals to make recommendations regarding the future use of the technique to identify the NV co-crystals.
Dissolution studies of the NV co-crystals prepared with maleic acid, salicylic acid and glutaric acid (NVMLE, NVSLI
and NVGLT, respectively) were completed using the rotating basket method. Assays were conducted using High
Performance Liquid Chromatography and compared to pure NV and the five NV: co-former mixtures. The antiviral
activity was tested to determine whether the co-crystals had an improved activity against HIV-1 compared to pure
NV.
All co-crystals, except NVTTA (a NV co-crystal prepared with rac-tartaric acid), were pure and maintained their
integrity for approximately one year. NVGLT, NVMLE and NVTTA, 1:1 molar ratio co-crystals were identified by
FTIR. The C=O stretching frequency of the carboxylic acid groups of NV and GLT were observed at 1638.15 cm-1
and 1719.23 cm-1 in the NVGLT co-crystal which corresponded with spectra of NVMLE and NVTTA. In NVMLE the
C=O stretching frequency of the C=O of NV and MLE were observed at 1640.58 cm-1 and 1694.10 cm-1 and in
NVTTA it was at 1637.25 cm-1 and 1708.50 cm-1, suggesting the presence of both parent molecules in the new
phase for NVGLT, NVMLE and NVTTA.
Dissolution studies suggested that NVGLT was the only co-crystal that yielded better results than both NV and its
physical mixture. The antiviral activity of the NVSC (an NV co-crystal prepared with saccharin) and NVSLI co-
crystals in DMSO was significantly different to pure NV, demonstrating an improvement in anti-viral activity.
Keywords: Co-crystals; Nevirapine; Dissolution rate; Scale-up;
Antiviral activity; FTIR; Solubility
Introduction
Nevirapine (NV) is a non-nucleoside reverse transcriptase inhibitor
used in combination with other antiretroviral drugs for the treatment
of Human Immunodeficiency Virus (HIV) infections. NV directly
inhibits reverse transcriptase activity therefore suppressing DNA
replication of the HIV virus and is known to prevent HIV transmission
from mother to infant. A single dose of NV administered to the
mother at the onset of labour and to the baby within 72 hours of
delivery nearly halved the rate of HIV transmission. Since NV is given
only once to the mother and baby it is relatively cheap and easy to
administer [1-3].
NV is practically insoluble in water with an aqueous solubility of 0.1
mg/ml-1 (pH 7, Temp. 37°C). According to the Biopharmaceutical
Classification Index, NV is a Class II drug i.e. it has a high permeability
and a low solubility [1]. The low rate of dissolution of NV is assumed
to be the rate-limiting step for absorption of the drug [4].
Co-crystals, a crystalline structure, containing two or more different
components in a definite stoichiometric ratio was investigated to
enhance the solubility, bioavailability and the dissolution rate of NV.
Co-crystals are formed between a molecular or ionic active
pharmaceutical ingredient (API) and a co-crystal former, where each
component is a solid at ambient temperature and produces a solid
product at ambient temperature as well [5]. Co-formers were selected
according to hydrogen bonding rules to facilitate non-covalent
bonding between molecules. NV co-crystals were formed with
Generally-Regarded-As-Safe (GRAS) compounds, namely Saccharin
(SC), Tac-Tartaric Acid (TTA), Maleic Acid (MLE) and Salicylic Acid
(SLI). Glutaric Acid (GLT) was also used as a co-former to form NV
co-crystals. NVSC and NVSLI formed co-crystals with a 2:1 ratio of
NV to the relevant co-former. NVTTA, NVMLE and NVGLT formed
co-crystals with a 1:1 ratio of NV to the relevant co-former [1].
In a similar study, the formulation of nicotinamide-based co-
crystals of fenofibrate by different methods in 1:1 molar ratio were
used to formulate molecular complexes by kneading, solution
crystallization, antisolvent addition and solvent drop grinding. The
prepared molecular complexes were characterized by powder X-ray
diffractometry, differential scanning calorimetry, Fourier transform
infrared spectroscopy (FTIR), nuclear magnetic resonance
spectroscopy and in vitro dissolution analysis. The analytical
techniques have all been widely employed to distinguish between
different crystal forms such as polymorphs, clathrates, hydrates and
co-crystals. FTIR has also been used to monitor co-crystal formation
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This study expands on the previous study by determining the
dissolution of the three co-crystals not previously tested, namely
NVMLE, NVSLI and NVGLT. FTIR spectroscopy was examined as a
technique to identify the co-crystals. Finally, the five co-crystals were




All co-crystals, pure NV and co-formers were donated by the
original research group responsible for their preparation Caira et al.
[1]. The integrity and purity of all co-crystals were verified using hot
stage microscopy (HSM) prior to experimentation.
A Linkam TH MS600 Temperature control stage connected to a T95
Linkpad System Controller was used to heat crystals at a controlled
rate of 20°C per minute commencing at room temperature until
degradation temperature of the product had been reached. Visual
characterisation was captured by an Olympus UC30 colour video
camera fitted to an Olympus SZX7 stereoscopic microscope. The
recorded images were analysed by Stream Essentials® software.
Fourier transform infrared spectroscopy
Fourier Transform Infrared (FTIR) spectroscopy was conducted to
confirm the identity of the five co-crystals and to determine whether
FTIR could be used in future co-crystal studies to identify co-crystal
forms.
IR spectra were collected for all five co-crystals, NV and each of the
co-formers. Each sample was manually ground and a sufficient amount
was placed on a PerkinElmer Spectrum 400 FTIR Spectrometer. The
spectral range was between 400-4000 cm-1 and spectral resolution was
0.4-65 cm-1. Wavelength repeatability was ± 0.02 cm-1 at 1,600 cm-1
with wavelength accuracy being ± 0.1 cm-1 at 1,600 cm-1. All spectra
were recorded in triplicate to ensure reproducibility of data. No
preparation of sample was required due to the simplified analysis of
powders and difficult solid materials using the PerkinElmer Spectrum
400 FTIR. Solid samples were placed directly onto the sample orifice
and held in position with a strong steel handle. Sample sizes were
between 5 to 10 mg with no destruction of the sample. The spectra
were produced and analysed using Spectrum software version 6.3.5.
Dissolution testing
Dissolution: Dissolution studies were conducted for NV alone, the
co-crystals NVSLI, NVGLT and NVMLE, as well as separate mixes of
NV with SLI, GLT and MLE (NV:SLI, NV:GLT and NV:MLE) in a 1:1
ratio. To ensure reproducibility these studies were conducted using the
rotating basket method previously used by Caira et al. [1]. The powder
mixtures and co-crystals were ground for 5 minutes before
encapsulation to ensure a particle size range of 65-200 µm. Gelatin
capsules were used to encapsulate 10 mg of NV, 10 mg of each of the 5
co-crystals and 10 mg of each mixture at a 1:1 molar ratio.
Tests were carried out in a Distek evolution 6100 dissolution system
with the temperature maintained at 37˚C. Flasks (900 ml) filled with
Reverse Osmotic water were used and a stirring speed of 100 rpm was
applied. The capsules were placed in stainless steel baskets to prevent
floating. A 3 hour run was conducted with 5 ml samples being filtered
for analysis at 15 minute intervals. The assays were performed by
HPLC.
High performance liquid chromatography
A standard curve of NV was generated as follows: 10 ml of 3 M
HCL in 1 litre of distilled water was dissolved. To create a stock
solution, 55.5 mg of NV was dissolved in 100 ml of this solution in a
100 ml volumetric flask. 4 ml of the stock solution was diluted to 200
ml with MilliQ water. The standard was performed in duplicate to
ensure accuracy. A linearity test was performed using a serial dilution
of the stock solution. A regression line with an r2=0.9969 was obtained.
The HPLC assay for NV was achieved using an all-in-one system, the
Shimadzu LC 2010 AHT system with Class VP software. The HPLC
assays for the co-crystals and the mixes were performed using an
Agilent 1200 system with Waters Empower software. The system
consisted of an Auto injector with heater (G1316A), a Diode Array
detector VL (G1329A) and a Quaternary pump (G1315D) as the
solvent delivery module. The column used was a Phenomenex Luna 5u
C18, 100A and the flow rate was set to 1 ml per minute with a column
temperature maintained at 35°C [2]. The injection volume was set at 10
µL. The mobile phase was prepared by dissolving 14.38 g of
ammonium phosphate buffer with 4 litres of MilliQ water. This was
stirred with a magnetic stirrer until the ammonium phosphate buffer
had dissolved. The buffer was placed into a 5 litre volumetric flask and
the pH was adjusted to 5 using 1 M NaOH. The solution was then
made up to 5 litres using MilliQ water. The mobile phase was filtered
through a 0.45 µm filter with compressed air.
Antiviral testing
Antiviral testing on the five co-crystals were carried out at the
National Institute of Communicable Diseases (NICD).
Cytotoxicity Screen: Toxicity screening was conducted to determine
if the co-crystals were cytotoxic towards the NICD’s specific 293T cells.
Toxicity can be reflected by cell viability. This is measured by the
bioreduction of a tetrazolium compound, Thiazolyl Blue Tetrazolium
Bromide (MTT) (Sigma), to a coloured formazan product in the
culture medium. Dead cells do not cause this colour change. The
formazan product is spectrophotometrically quantified and the degree
of toxicity is related to the MTT-to-formazan conversion by the cells.
Stock solutions of each co-crystal and pure NV were prepared using
dimethyl sulfoxide (DMSO) to contain an effective NV concentration
of 10 mM. The stock solution was diluted to working concentrations in
complete Dulbecco's Modified Eagle's medium (DMEM) with Fetal
Bovine Serum (FBS), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) and antibiotics. A dimethyl sulfoxide (DMSO) control
solution was prepared which was run in parallel. The working solution
was titrated into complete DMEM medium by serial dilution in a 96-
well culture plate, providing a range of concentrations for toxicity
testing. A control cell was included. The culture plate was incubated for
2 days at 37°C under 5% CO2 in a humidified atmosphere. MTT
reagent was added and the plates were incubated for approximately 1
hr. A solution of sodium dodecyl sulphate (10%) and
dimethylformamide (50%) was added to lyse the cells and dissolve the
formazan crystals. The spectro-photometric absorbance of each well
was read at 490 nm, with 650 nm chosen as the reference wavelength.
The percentage viability was then calculated. A viability of 0% indicates
total cell death while a viability of 100% indicates full cell viability.
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Activity screen: The antiviral activity of the co-crystals to HIV-1
pseudovirus in relation to pure NV was tested. This assay investigated
the inhibition of viral replication in a single cycle of infection. The
pseudovirus contains HIV-1 sub-type C reverse transcriptase, integrase
and protease as well as a RNA transcript of the firefly luciferase
protein. During infection, reverse transcription of the RNA by the
HIV-1 reverse transcriptase to complementary DNA occurs, which is
then integrated into the host cell’s DNA by HIV-1 integrase. The firefly
luciferase gene is expressed to produce active firefly luciferase which
can be assayed through a bioluminescence reaction. This reaction can
be quantified. The signal is directly proportional to the number of
infectious viruses in the inoculum. In the presence of an inhibitor, in
this case NV, the number of firefly luciferase gene copies that are
integrated into the genome will be reduced, thereby decreasing the
amount of bioluminescence observed.
The non-toxic concentration of each co-crystal, as determined by
the toxicity screen, was used to determine the activity. The co-crystal
solution was diluted in complete DMEM medium to contain a final
effective NV concentration of 18 µM, the highest non-toxic
concentration. Eleven three-fold serial dilutions of each sample stock
was prepared, starting at 18 µM, these dilutions were then titrated into
a 96-well culture plate. Cells and virus were added and the plates were
then incubated for 48 hours at 37°C under 5% CO2 in a humidified
atmosphere. The co-formers were diluted and prepared to
concentrations which were similar to the co-crystal solutions. A virus
control was included in the test, which contained only cells, virus and
medium. A DMSO solvent control was also included. The antiviral
activity of the co-crystals was screened using a standard HIV-1 subtype
C isolate. Following incubation, Bright Glo™ Reagent was used to assay
for the firefly luciferase in the wells. A luminometer was then used to
quantify the bioluminescence emitted. The percentage of viral activity
was then calculated. A viral activity of 0% would indicate complete
viral inhibition, while that of 100% would indicate no inhibition. The
inhibitory concentration-50 (IC50) value indicates the concentration of
co-crystal where 50% of the virus is inhibited. A dose-response curve
was used to obtain these values. The activity screen was performed in
duplicate.
The average and standard deviation of the IC50 of the two runs was
calculated using Microsoft Excel. An unpaired two-tailed t-test with
95% confidence intervals was performed using GraphPad Prism 4, in
order to determine if a significant difference occurs between the viral
activity of the co-crystals and pure NV.
Results and Discussion
Hot stage microscopy
In Figure 1a and b, the first sign of melting for NVSC occurred at
223°C and complete melting was observed at 230°C, this data
corresponds to that achieved in the previous study. This result suggests
that NVSC had maintained its integrity and purity and could be used
in further experiments. According to M.R. Caira et al., NVTTA was
expected to melt at 230°C. The NVTTA tested began to spontaneously
bubble at a temperature of 100°C. A yellow discolouration appeared at
a temperature of 140°C. The spontaneous bubbling continued, with the
co-crystal turning an orange-brown colour at 230°C (Figure 2a and b).
The NVTTA had degraded; and could no longer be used for further
experiments since the sample had lost its purity and integrity. A new
batch of NVTTA was manufactured. All other co-crystals maintained
their purity and integrity.
Figure 1: NVSC co-crystals at room temperature (25°C) (a) and at
230°C (b).
Figure 2: NVTTA co-crystals at (25°C) and (b) 230°C showing
brown discolouration.
Fourier transform infrared spectroscopy
The FTIR spectrum of each co-crystal was compared to NV and its
relevant co-former. A wavelength shift of a peak or a change in peak
intensities between the spectra would suggest that a co-crystal had
formed. These peaks are a representation of the bonding points of the
two molecules and are expected to occur at the C=O, O-H and N-H
groups of the active pharmaceutical ingredient and co-former C=O
peaks occur between 1680-1 750 cm-1 (Figure 3a-e). NV and all co-
formers peaks were identified in this region and compared in the co-
crystal (Table 1). The FTIR spectrum of NV showed its C=O stretch at
1643.64 cm-1. GLT, MLE and TTA, C=O peaks appeared at 1686.05
cm-1, 1704.09 cm-1 and 1723.98 cm-1, respectively (Table 1).
  NVGLT NVMLE NVTTA
NV 1643.64 cm-1 1638.15 cm-1 1640.58 cm-1 1637.25 cm-1
GLT 1686.05 cm-1 1719.23 cm-1   
MLE 1704.09 cm-1  1694.1 cm-1  
TTA 1723.98 cm-1   1708.5 cm-1
Table 1: Shifts observed in the C=O peaks for NVGLT, NVMLE and
NVTTA.
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Figure 3: Co-crystals NVSC (a), NVTTA (b), NVMLE (c), NVGLT (d) and NVSLI (e) showing the bonds involved in the shift of the IR peaks.
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The C=O stretching frequency of the carboxylic acid groups of NV
and GLT were observed at 1638.15 cm-1 and 1719.23 cm-1 in the
NVGLT co-crystal (Figure 4a-c). This was also observed in the FTIR
spectrum of NVMLE and NVTTA co-crystals. In NVMLE the C=O
stretching frequency of the carboxylic acid group of NV and MLE were
observed at 1640.58 cm-1 and 1694.10 cm-1 (Figure 5a-c) and in
NVTTA the C=O stretching frequency of the carboxylic acid group of
NV and TTA were observed at 1637.25 cm-1 and 1708.50 cm-1 (Figure
6a-c). These results indicate the presence of both parent molecules in
the new phase for NVGLT, NVMLE and NVTTA.
In a study by S. Basavoju et al. (2007)7 FTIR was used to identify co-
crystals of indomethacin and SC by comparing the C=O, O-H and N-
H peaks in the spectra of the co-crystal with those of the parent
compounds. In this study the Spectrum software utilized (version
6.3.5) did not identify the O-H or N-H peaks as expected, however
shifts and change in intensity of peaks were identified. These results in
the FTIR spectra of SLI a C=O peak occurs at 1654.88 cm-1, however
this peak is not represented in the spectra of the NVSLI co-crystal. This
could be because the NVSLI co-crystal forms a 2:1 ratio, which could
indicate that the C=O bonds from the 2 NV molecules are
superimposed on the SLI’s C=O bond (Figure 7a-c). This phenomenon
is also present in the NVSC co-crystal which also forms a 2:1 ratio. A
shift in the C=O bond from the co-former is not observed in the co-
crystal (Figure 8a-c).
Figure 4: FTIR spectra of (a) GLT, (b) NV and (c) NVGLT co-crystals.
Following these results, we find that FTIR can be used for the
identification of co-crystals creating a database of potential co-crystals
with single X-ray diffraction analysis used as confirmation of the
result. However, each API and relevant co-former will produce a
different shift in the co-crystal and caution should be used when
attempting to identify co-crystals when the co-crystal is known to
form in a 2:1 ratio. The Spectrum software used should be able to
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detect the bonds involved when the API and co-former bind to form
the co-crystal (Figure 3).
Figure 5: FTIR spectra of (a) MLE, (b) NV and (c) NVMLE co-crystals.
Dissolution testing
In vitro dissolution tests for co-crystals NVGLT, NVSLI and
NVMLE were conducted to compare their dissolution to their
respective NV-co-former mixtures and the untreated API. The
dissolution profile (Figure 9) of NV improved for both the co-crystals
and the physical mixtures. NVGLT was the only co-crystal that yielded
better results than both NV and its physical mixture. However, NVGLT
and its physical mixture still did not comply with the British
Pharmacopoeia 2005 (BP) standards in that 75% of the substances did
not go into solution within 45 minutes [6-8]. Only 30% and 26% went
into solution after 45 minutes for NVGLT co-crystal and NV:GLT
mixture, respectively. The NV:SLI and NV:MLE physical mixtures had
better dissolution profiles compared to their co-crystals.
Caira et al. used the dissolution-time curves of NVSC and NVTTA
to determine the solubility enhancement parameter of these co-
crystals. It was estimated that the NVMLE co-crystal would produce
the highest increase in aqueous solubility of NV, that of a ~five-fold
increase. The experimental dissolution results disprove this as only
39% of NVMLE went into solution after 180 minutes, corresponding to
a ~two-fold increase. In comparison, 54% of NV:MLE went into
solution after 180 minutes.
The increase in aqueous solubility of NV produced by NV: SLI was
twice as much as the increase produced by NVSLI. NVSLI had a total
dissolution of only 32% while NV: SLI had a total dissolution of 65%.
The NV: SLI physical mixture had the best dissolution profile,
producing the highest percentage total dissolution and having the
fastest rate of dissolution compared to all other samples.
As seen by Figure 9, NV alone had a total dissolution of only 16%.
This was not expected, since Caira et al. showed a dissolution of
approximately 60%. It is important to note that 100% pure NV was
used, and the NV used in both studies was from the same batch. The
discrepancy in the dissolution profiles of NV could be due to the fact
that different analytical methods were used for the dissolution assay.
The previous study used UV spectrophotometry at 234 nm1, while
HPLC was used in this study. UV spectra show peaks at varying
wavelengths but only one is chosen and thus does not have the same
degree of specificity as HPLC. In comparison, HPLC produces results
for a distinct retention time only, and is thus more precise and
accurate. No validation was done to prove that the methods would
produce similar results.
Citation: Samsodien H, Bapoo M, Doms Tl, Harneker Z, Louw AS, et al. (2017) FTIR, Dissolution and Anti-viral Activity of Nevirapine Co-
crystals. Pharm Anal Acta 8: 561. doi:10.4172/2153-2435.1000561
Page 6 of 10
Pharm Anal Acta, an open access journal
ISSN: 2153-2435
Volume 8 • Issue 9 • 1000561
Figure 6: FTIR spectra of (a) TTA (b) NV and (c) NVTTA co-crystals.
Figure 7: FTIR spectra of (a) SLI, (b) NV (c) NVSLI co-crystals.
Citation: Samsodien H, Bapoo M, Doms Tl, Harneker Z, Louw AS, et al. (2017) FTIR, Dissolution and Anti-viral Activity of Nevirapine Co-
crystals. Pharm Anal Acta 8: 561. doi:10.4172/2153-2435.1000561
Page 7 of 10
Pharm Anal Acta, an open access journal
ISSN: 2153-2435
Volume 8 • Issue 9 • 1000561
Figure 8: FTIR spectra of (a) SC, (b) NV and (c) NVSC co-crystal.
Figure 9: Dissolution profiles of selected NV co-crystals and
mixtures.
A possible theory for the improved dissolution of the physical
mixtures is based on the fact that the co-formers used in the
dissolution study are weak acids and thus dissociate when added to
water. The dissociation constant (pKa) is the degree to which an acid
dissociates into water, the larger the pKa the smaller the extent of
dissociation. Once an acid dissociates it lowers the pH of the solvent.
NV is a weak base (pKa=2.8) which has better solubility in an acidic
medium [9]. A lowering of the pH of the solvent by the dissociation of
the co-formers in the mixes, will therefore increase the solubility of
NV.
In both Figure 9 and Table 2, NV: SLI has the greatest total
dissolution after 180 minutes. SLI has the smallest pKa value and thus
it dissociates to a greater extent than the other co-formers. The greater
extent of dissociation lowers the pH of the dissolution medium,






SLI 3 65 32
GLT 4.3 and 5.4 47 59
MLE 1.9 and 6.3 54 39
Table 2: pKa values and total percentage dissolution of NV physical
mixtures and co-crystals.
MLE, being a diprotic acid, has two hydrogen atoms per molecule
capable of dissociating. The dissociation of both hydrogen atoms does
not occur at the same time. The pKa of 6.3 refers to the dissociation of
only one hydrogen atom per MLE molecule. If both hydrogen atoms
were to dissociate to the full extent, the pKa value would be 1.9. On the
assumption that the first hydrogen atom fully dissociates and the
second hydrogen only partially dissociates, the pKa value would fall in
between the reference values. This explains why the total dissolution of
NV: MLE is less than NV: SLI but more than NV: GLT.
GLT is also a diprotic acid with pKa values of 4.3 and 5.4. The
higher pKa values of GLT compared to SLI means that it dissociates to
a lesser extent and does not decrease the pH of the medium as
significantly as SLI. This is proven by the total dissolution of NV: GLT
being only 47% compared to 65% of NV: SLI.
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From Table 2 we can deduce that the lower the pKa of the co-former
the better the solubility of NV when in a physical mixture. In
comparison, a high pKa value of the co-former results in better
solubility of NV when in the co-crystal form. This can be rationalized
by a difference in the mechanism which causes the mixes and co-
crystals to go into solution. Further research needs to be performed to
understand these exact mechanisms. A possible explanation is that
upon dissociation of the co-former and NV in co-crystal form, the
molecules will both go into solution immediately. This is different from
the mechanism which is displayed when the physical mixtures go into
solution. Here the acidic co-formers go into solution first and lowers
the pH of the solvent, creating a better environment for the NV to go
into solution.
A possible theory for the improved dissolution of the co-crystals is
based on a relationship between the melting point of the co-former
and that of its co-crystal. The melting point of a co-crystal for a given
API directly correlates with the melting points of the respective co-
formers (Figure 10) [1].
Figure 10: Melting points of NV co-crystals and the respective co-
formers [1].
Low thermal stability implies high water solubility [10]. NVGLT has
the lowest melting point and the best total dissolution (Table 2).
NVMLE has a significantly higher melting point than NVGLT, and
hence a significantly lower total percent dissolution. NVSLI’s melting
point is only slightly higher than that of NVMLE, and its dissolution is
also comparatively so. As can be seen from the results, the dissolution
profile of each co-crystal correlates to its melting point.
Antiviral testing
In vitro antiviral testing of the co-crystals are necessary to confirm
that the new crystalline form of NV has comparable or improved
activity against HIV-1. The co-crystals showed no significant
cytotoxicity to the 293T cells, as percentage viability remained above
50% for all co-crystals tested (Figure 11). The cytotoxicity-50 (CC50)
value is greater than the maximum concentration tested, indicating no
cytotoxic effect to the 293T cells. These concentration ranges were
therefore used when screening for anti-HIV-1 activity.
Figure 11: Cytotoxic effects of the NV co-crystals on the viability of
293T cells in vitro.
When testing the antiviral activity, the NICD confirmed that neither
the co-formers nor DMSO solvent inhibited HIV-1. This indicates that
the inhibitory activity displayed by the co-crystals is directly as a result
of the NV portion of the molecule. NVSC and NVSLI had an average
IC50 value of 0.037 mM, which differed significantly from pure NV
(0.083 mM), with p-values of 0.002. NVMLE and NVGLT had average
IC50 values of 0.055 mM and 0.054 mM significantly different from
pure NV with p-values of 0.026 and 0.019, respectively. NVTTA had an
average IC50 value of 0.072, which does not differ significantly from
pure NV, with a p-value of 0.416 (Figure 12).
Figure 12: Antiviral activity of the NV co-crystals against HIV-1,
compared to pure NV.
Conclusion
The results presented here indicate that FTIR is an appropriate
analytical method of identifying co-crystals except for co-crystals with
a 2:1 molecular ratio. Since the co-former and NV are held together by
weak hydrogen bonds, peaks were expected to occur at the C=O, O-H
and N-H bonds. The Spectrum software used in this study was only
able to detect the C=O bonds. The dissolution of NV was enhanced in
the presence of individual co-formers, both in co-crystal form and as a
physical mixture. NVGLT was the only co-crystal that yielded better
results than its physical mixture. The solubility studies indicate that the
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choice of co-formers for future research could possibly be based on
pKa and melting point values. HPLC proved to be a more accurate and
precise analytical method than UV spectrometry, producing more
reliable results. Finally, the NVSC, NVSLI, NVMLE and NVGLT HIV-1
anti-viral activity differed significantly from pure NV compared to
NVTTA.
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